A Study of 177Lu-PSMA-617 in People With Gliomas

This study is testing a radioactive drug called 177Lu-PSMA-617 — which is already approved for prostate cancer — in people with certain types of brain tumors called gliomas. The drug homes in on a protein called PSMA that some glioma tumors produce, delivering radiation directly to the tumor cells. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with a specific type of glioma (grade 2–4, IDH-wildtype, confirmed by biopsy) - Your tumor tests positive for the PSMA protein on a tissue test - You have already completed standard treatment including surgery and radiation therapy - Your kidney, liver, and blood counts are within acceptable ranges - You are on a low dose of steroids (4 mg dexamethasone or less) for at least 5 days before treatment **You may NOT be eligible if...** - Your tumor is located within 5 mm of the brainstem, optic nerves, or optic chiasm - You have received bevacizumab (Avastin) as part of your initial treatment - You have significant kidney disease (stage 2 or higher chronic kidney disease) - You are pregnant or plan to become pregnant - You have active HIV, hepatitis, or another serious active infection - Your life expectancy is less than 12 weeks Talk to your doctor to see if this trial is right for you.